BetterLife Pharma (TSE:BETR) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BetterLife Pharma Inc. has amended beneficial ownership information in past Management Information Circulars and announced the issuance of new shares and warrants following a convertible debentures conversion. The biotech company is advancing the development of non-hallucinogenic compounds, BETR-001 and BETR-002, aimed at treating various neuropsychiatric and neurological disorders.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue